Gamut Therapeutics SAS

GAMUT is a spin-out of the Institut de la Vision in Paris, focused on pioneering the unique research of scientific founder Dr. Deniz Dalkara and her collaborators. It was started in 2020 with seed funding from Advent France Biotechnology. Geoffroy de Ribains, Operating Partner at Advent France Biotechnology, is CEO of GAMUT Therapeutics. *

	Start	2020-07-01 established (s-off)
	Group	SparingVision SAS
	Industry	gene therapy eye disease
	Person	de Ribains, Geoffroy (AdBio Partners 202302– promoted to Managing Parnter joined AFB 2009 before Step Pharma + Biomunex)

	Region	Paris
	Country	France
	Street	4 rue Thenard
	City	75005 Paris
		Address record changed: 2021-04-22

Basic data	Employees	n. a.

		* Document for »About Section«: SparingVision SAS. (4/20/21). "Press Release: SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of Gamut Therapeutics". Paris.

		Record changed: 2024-09-08

Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x200px

More documents for SparingVision SAS

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]